1.07
price down icon5.31%   -0.06
pre-market  Vorhandelsmarkt:  1.14   0.07   +6.54%
loading
Schlusskurs vom Vortag:
$1.13
Offen:
$1.13
24-Stunden-Volumen:
981.57K
Relative Volume:
0.44
Marktkapitalisierung:
$17.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.90M
KGV:
-0.00519
EPS:
-206.0125
Netto-Cashflow:
$-12.75M
1W Leistung:
+3.88%
1M Leistung:
+2.88%
6M Leistung:
-29.14%
1J Leistung:
-26.71%
1-Tages-Spanne:
Value
$1.01
$1.16
1-Wochen-Bereich:
Value
$0.9501
$1.19
52-Wochen-Spanne:
Value
$0.1131
$3.95

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name
Firmenname
Allarity Therapeutics Inc
Name
Telefon
401-426-4664
Name
Adresse
24 SCHOOL ST., 2ND FLOOR, BOSTON
Name
Mitarbeiter
7
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ALLR's Discussions on Twitter

Vergleichen Sie ALLR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALLR
Allarity Therapeutics Inc
1.07 17.53M 0 -11.90M -12.75M -206.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Allarity Therapeutics Inc Aktie (ALLR) Neueste Nachrichten

pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 25, 2025

Allarity unveils new multiple myeloma treatment predictor - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Allarity unveils new multiple myeloma treatment predictor By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Healthy Upside Potential: Allarity Therapeutics Inc (ALLR) - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

Allarity Therapeutics Presents Novel Drug Response - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Novel AI Predictor Identifies Multiple Myeloma Patients for Targeted Treatment | ALLR Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 23, 2025

Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX

Apr 23, 2025
pulisher
Apr 22, 2025

How to interpret Allarity Therapeutics Inc (ALLR)’s stock chart patterns - uspostnews.com

Apr 22, 2025
pulisher
Apr 21, 2025

Allarity Therapeutics Inc (ALLR) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Apr 21, 2025
pulisher
Apr 16, 2025

Allarity Therapeutics Restructures Board of Directors - TipRanks

Apr 16, 2025
pulisher
Apr 14, 2025

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire

Apr 14, 2025
pulisher
Apr 10, 2025

Allarity Therapeutics stock hits 52-week low at $0.67 - Investing.com

Apr 10, 2025
pulisher
Apr 09, 2025

Allarity Therapeutics stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News

Apr 08, 2025
pulisher
Apr 08, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 04, 2025

Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - Stocksregister

Apr 04, 2025
pulisher
Apr 03, 2025

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter

Mar 31, 2025
pulisher
Mar 26, 2025

Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics probes potential stock manipulation - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan

Mar 24, 2025
pulisher
Mar 20, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 20, 2025
pulisher
Mar 19, 2025

ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM

Mar 19, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity reports promising ovarian cancer trial results - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 17, 2025

Can you now get a good deal on Allarity Therapeutics Inc’s shares? - uspostnews.com

Mar 17, 2025
pulisher
Mar 14, 2025

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com

Mar 14, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures -March 13, 2025 at 09:18 am EDT - Marketscreener.com

Mar 13, 2025

Finanzdaten der Allarity Therapeutics Inc-Aktie (ALLR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Kapitalisierung:     |  Volumen (24h):